The AntibioTx team and advisors account for more than 20 drug approvals generating annual revenues in excess of 5 B USD.


Rasmus Toft-Kehler, Chief Executive Officer

Rasmus Toft-Kehler has been directly and indirectly involved with a number of new ventures including being the co-founder of Clinical-Microbiomics A/S. Prior to his entrepreneurial career, Rasmus worked in M&A (Goldman Sachs and Gudme Raaschou), management consulting (Booz Allen Hamilton) and in a family-owned enterprise which was successfully sold in 2005.

Rasmus holds an executive degree in entrepreneurial leadership from Harvard Business School and a degree in finance and business administration from New York University and Copenhagen Business School. Rasmus’ research on serial entrepreneurship has been taught at Harvard Business School and published in leading entrepreneurship journals.

In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.


Morten Sommer, Chief Scientific Officer

Morten Sommer is the founder and co-founder of four biotech companies, including Microlytic founded in 2006 which served over 150 customers, including 9 of the 10 largest pharmaceutical companies in the world. The company was sold in a cross-border transaction in 2015.

Morten is also a Professor at the Technical University of Denmark with a lab of 30 PhD's and Post docs working primarily in the field of antibiotic resistance. Morten is the inventor on 10+ issued patents, patent applications and author of scientific papers in journals such as Science and Nature.

Dr. Sommer holds a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.


Dr. Philippe Prokocimer, Chief Medical Officer

Dr. Philippe Prokocimer, M.D. is the Chief Medical Officer of AntibioTx. Dr. Prokocimer was Officer of Trius Therapeutics from July 2007 until its acquisition by Cubist in 2014. At Cubist, Dr. Prokocimer became Senior Vice President of Clinical Development until the acquisition by Merck in January 2015. At Merck, he became Associate Vice President of Clinical Development, Head of San Diego site.

Dr. Prokocimer has been developing anti-infective drugs for 30 years and has been involved with successful approval of 6 New Drug Applications including 5 antibiotics: Doripenem (Doribax®), Quinupristin/dalfopristin (Synercid®), Sparfloxacin (Zagam®), Clarithromycin (Biaxin®) and Tedizolid Phosphate (Sivextros®). Dr. Prokocimer received an M.D. degree from the School of Medicine in Paris, France and a Post-Doctoral Research Fellowship from Stanford University.


Dr. Lutz Wevelsiep, VP of Regulatory Affairs

Dr. Lutz Wevelsiep, Ph.D. is the Vice President of Regulatory Affairs in AntibioTx and has more than 25 years’ experience in international Regulatory Affairs across Europe and the US within multinational and start-up companies. His experience includes EU decentralized and centralized procedures, product development from Phase I through to marketing authorization as well as particular expertise in anti-infectives. He has prepared and managed various health authority interactions with FDA, EMA and EU national agencies.

Lutz has spent 16 years as Head of Global Regulatory Affairs at Basilea Pharmaceutica. His track record includes successful completion of the European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®). Lutz holds a Ph.D. and Postdoc in chemistry from the Max-Planck Institute in Germany.


Morten Just, VP of Drug Development

Morten Just Petersen has prior experience from multiple drug development projects and has been involved with all stage of development with particular emphasis on regulatory interactions, clinical study design, CMC and execution.

Morten was the COO and later CEO of Astion Pharma A/S. During his time with the company he was in charge of bringing a topical product from the conceptual stage through development and registration before successfully selling the company through a cross-border transaction in 2015.

In 1996 Morten completed an M. Sc. in Chemistry from the University of Copenhagen and subsequently did a post-graduate MBA with emphasis on drug development from the University of Copenhagen.


Jan Trofast, VP of Patent Strategy

Jan Trofast is the co-inventor of Symbicort (annual >4 Billion USD) and the strategist behind a highly successful patent portfolio of 25+ patents protecting Symbicort and related products. Symbicort is expected to become AstraZeneca’s best selling drug - despite core patent expiration.

Jan Trofast has more than 30 years of experience from AstraZeneca including a number of years with evaluation of internal and external projects.

Jan Trofast obtained a Ph.D. in Organic Chemistry in 1978 and is the author of a significant scientific literature including several publications related to Jacob Berzelius. For his contributions he has been rewarded the Berzelius medal in gold by the Royal Swedish Academy of Sciences in 2001 and the Swedish Medicinal Chemistry Award by the Swedish Pharmaceutical Society in 2010.


Learn more